It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the
forecast period of 2017-2023. Evans syndrome is a rare autoimmune disorder in which the
body’s immune system produces antibodies that destroy red blood cells (RBCs), platelets and
sometimes white blood cells (WBCs) known as neutrophils. Major symptoms associated with
Evans syndrome include jaundice, bloody nose, fever, weakness, bacterial infections and many
others. A number of factor such as rising prevalence of autoimmune disorders, increasing
awareness, improving regulatory framework, increasing government assistance, increasing
automation of laboratories, and rising funding and reimbursement policies are propelling the
growth of the global Evan syndrome market.
Request Sample Copy:
However, challenges in research and development, side-effects of treatment, the presence of
misbranded and spurious drugs and poor healthcare system in low and middle-income
countries may hamper the growth of the market.
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy,
antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells,
and others. The blood test is further segmented into complete blood count (CBC), and direct
antiglobulin test. On the basis of the treatment, the market is classified as pharmacologic
therapy, splenectomy, biologic therapy, stem cell transplantation, and others. The
pharmacologic therapy is further sub-segmented into Prednisone and intravenous
immunoglobulin (IVIg) therapy. The biologic therapy is sub-segmented into Rituximab and
On the basis of the distribution channel, the market is segmented into hospitals, clinics,
diagnostic centers, drug stores, pharmacies, and others.